# US 2008/0305494 A1 · Chemokine Ccl18 as a Biomarker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305494 A1
- Document ID: US20080305494A1
- Status: Published application
- Kind: A1
- Application number: 10/592,831
- Filed: 2005-03-21
- Published: 2008-12-11
- Earliest claimed: 2004-03-22
- Inventors: Jose M. Carballido Herrera; Claudia Guenther
- Web page: https://patentgrep.com/patent/US20080305494A1

## CPC

- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/202: Dermatitis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a diagnostic tool, e.g. to the chemokine CCL18 as a biomarker in a sample of a body fluid of an individual and its use in various methods.

## Claims

### Claim at position 1

1: The chemokine CCL18 for use as a biomarker in a sample of a body fluid of an individual.

### Claim at position 2 (depends on 1)

2: The chemokine of claim 1 for use as a biomarker in a sample of a body fluid of an individual for a disorder or disease selected from the group consisting of allergic disease and Th2 mediated disorder.

### Claim at position 3 (depends on 1)

3: The chemokine of claim 1 wherein the disorder or disease is related with atopic dermatitis.

### Claim at position 4

4: Method for screening and/or in vitro diagnosing of a disorder or disease selected from the group consisting of allergic disease and Th2 mediated disorder in an individual, which method comprises
a) providing a sample of a body fluid of an individual,
b) determining the level of CCL18 in said sample as provided in step a),
c) comparing the level of CCL18 as determined in step b) with a reference level from a sample of a body fluid of a healthy control individual, and
d) screening and/or in vitro diagnosing a disorder or disease selected from the group consisting of allergic disease and Th2 mediated disorder in determining whether the level of said CCL18 as determined in step b) is significantly different from said reference level.

### Claim at position 5 (depends on 4)

5: A method of claim 4 wherein the level of CCL18 is determined in using a CCL18 specific antibody.

### Claim at position 6

6: Method for monitoring the therapeutic efficacy of the treatment of an individual with a substance which is expected to have an effect on reducing or curing a disorder or disease selected from the group consisting of allergic disease and Th2 mediated disorder, which method comprises determining the level of CCL18 in a sample of a body fluid of said individual and comparing it to the level of CCL18 prior to administration of said substance.

### Claim at position 7

7: Kit for screening and/or in vitro diagnosing of a disorder or disease selected from the group consisting of allergic disease and Th2 mediated disorder in a sample of a body fluid of an individual comprising
a) a molecule which recognizes CCL18 protein or a part thereof, optionally in a labeled form,
b) instructions for use,
c) optionally detection means, and
d) optionally a solid phase.
